Elotuzumab
Empliciti (elotuzumab) is an antibody pharmaceutical. Elotuzumab was first approved as Empliciti on 2015-11-30. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against SLAM family member 7.
| Trade Name | Empliciti |
|---|---|
| Common Name | Elotuzumab |
| Indication | multiple myeloma |
| Drug Class | Monoclonal antibodies: humanized, tumors as target |
